Krystal Biotech Reports Earnings Beat but Revenue Misses Estimates
Krystal Biotech (NASDAQ:KRYS) reported second-quarter 2026 results that exceeded earnings expectations with adjusted EPS of $1.79, surpassing the consensus estimate by $0.09. However, revenue came in at $119.2 million, below Wall Street's forecast of $122.3 million and down from analysts' predictions despite a 24% year-over-year increase to sales. The stock fell nearly 7.65% in pre-market trading following the mixed results. The company highlighted strong performance for its flagship product VYJUVEK, which achieved a 95% gross margin and is expanding internationally with expected launches in Italy and Spain by year-end. CEO Krish S. Krishnan emphasized commercial momentum and pipeline progress as key drivers of growth. Krystal also provided full-year expense guidance between $175 million to $195 million for combined R&D and SG&A costs, excluding stock-based compensation. Krystal ended the quarter with a robust cash position of approximately $1.1 billion in cash, equivalents, and investments.
Tickers: $KRYS